Enhertu Approved in the EU for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.